News
ANIX
3.050
+5.54%
0.160
Buy Rating Affirmed for Anixa Biosciences Amid Promising Cancer Therapy Trials
TipRanks · 2d ago
ANIXA BIOSCIENCES ANNOUNCES FDA APPROVAL OF INDIVIDUAL PATIENT IND FOR ITS OVARIAN CANCER CAR-T THERAPY
Reuters · 3d ago
EXCLUSIVE: FDA Approves Anixa Biosciences' Individual Patient Trial Application For Ovarian Cancer CAR-T Therapy
Anixa Biosciences has received FDA approval for a CAR-T therapy for an individual patient. Anixa has authorized a share repurchase program of up to $5 million. The company's collaborator, Moffit Cancer Center, is treating ovarian cancer patients.
Benzinga · 3d ago
Weekly Report: what happened at ANIX last week (0715-0719)?
Weekly Report · 4d ago
ANIXA BIOSCIENCES INC - VACCINE CURRENTLY BEING STUDIED IN PHASE ONE CLINICAL TRIAL AT CLEVELAND CLINIC
Reuters · 07/17 12:00
ANIXA BIOSCIENCES ANNOUNCES JAPANESE PATENT ON BREAST CANCER VACCINE TECHNOLOGY
Reuters · 07/17 12:00
Anixa Biosciences authorizes $5M share buyback program
Seeking Alpha · 07/15 12:43
Press Release: Anixa Biosciences Announces $5 Million Share Repurchase Program
Dow Jones · 07/15 12:30
*Anixa Biosciences Announces $5 Million Share Repurchase Program >ANIX
Dow Jones · 07/15 12:30
EXCLUSIVE: Anixa Biosciences Finds Stock Undervalued, Launches $5M Stock Buyback Program
Anixa Biosciences has authorized a share repurchase program of up to $5 million of the company's outstanding common stock. The company is a biotechnology company focused on the treatment and prevention of cancer. Anixa believes its stock is currently undervalued.
Benzinga · 07/15 12:00
Weekly Report: what happened at ANIX last week (0708-0712)?
Weekly Report · 07/15 10:06
Weekly Report: what happened at ANIX last week (0701-0705)?
Weekly Report · 07/08 10:07
Weekly Report: what happened at ANIX last week (0624-0628)?
Weekly Report · 07/01 10:07
ANIXA BIOSCIENCES TREATS SIXTH PATIENT IN ITS OVARIAN CANCER CAR-T CLINICAL TRIAL
Reuters · 06/24 12:45
Weekly Report: what happened at ANIX last week (0617-0621)?
Weekly Report · 06/24 10:11
Weekly Report: what happened at ANIX last week (0610-0614)?
Weekly Report · 06/17 10:06
U.S. RESEARCH ROUNDUP-ACV Auctions, Asbury Automotive Group, Walmart
Wall Street analysts revise ratings and price targets on several US-listed companies. Acv Auctions, Asbury Automotive Group, Walmart among companies with revised targets. Air Products and Chemicals, Adobe and Coca-Cola among the companies with new targets for the day.
Reuters · 06/10 14:14
Anixa Biosciences Price Target Cut to $7.00/Share From $12.00 by HC Wainwright & Co.
Dow Jones · 06/10 10:52
Anixa Biosciences Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 06/10 10:52
HC Wainwright & Co. Maintains Buy on Anixa Biosciences, Lowers Price Target to $7
Benzinga · 06/10 10:42
More
Webull provides a variety of real-time ANIX stock news. You can receive the latest news about Anixa Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About ANIX
Anixa Biosciences, Inc. is a biotechnology company developing vaccines and therapies that are focused on critical unmet needs in oncology. Its segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Other. Its vaccine programs include the development of a preventative vaccine against triple negative breast cancer (TNBC), the most lethal form of breast cancer, as well as other forms of breast cancer and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T cell therapy, a novel form of chimeric antigen receptor T cell (CAR-T) technology, initially focused on treating ovarian cancer, which is being developed by its subsidiary, Certainty Therapeutics, Inc. (Certainty). Certainty is developing immuno-therapy drugs against cancer. The Company’s vaccine portfolio consists of technology focused on the immunization against specific retired proteins.